Hot on the tail of AstraZeneca’s Imfinzi, Bristol Myers Squibb’s PD-1/L1 inhibitor Opdivo has expanded its non-small cell ...

While Mounjaro was cleared for use in England last year, Lilly put its launch on hold until its pre-filled injection device, ...

After unlocking commercial supply and enlisting a manufacturing partner earlier this year, Ferring Pharmaceuticals has ...

Eli Lilly’s juggernaut diabetes and obesity drugs Mounjaro and Zepbound have been erased from the FDA’s shortage list, ...

With a recently acquired FDA nod for its Halozyme Therapeutics-partnered Vyvgat Hytrulo, argenx is looking to take Halozyme’s ...

As the BIOSECURE Act works its way through the U.S. legislative branch, two companies named in the bill are reportedly ...

For the biotech formerly known as Eliem Therapeutics, it’s all about the climb—Climb Bio, that is. | For the biotech formerly ...

Real Chemistry has partnered with Corval to add a commercialization planning and launch platform to its offering. The ...

While they were both approved several years back to treat the same two types of prostate cancer, Astellas and Pfizer’s Xtandi ...

Gilead Sciences is wasting no time in promoting worldwide access to its twice-yearly pre-exposure prophylaxis (PrEP) HIV ...

Lucid is planning on bringing #CheckYourFoodTube events to more ex-NFL stars in cities across the U.S., with a goal of ...

Roughly a year and a half after the introduction of a damning shareholder lawsuit, Amgen has lost its bid to toss the case ...